story of the week
Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma
J. Clin. Oncol 2022 May 01;40(13)1393–1395, R Dummer, GV Long, C Robert, HA Tawbi, KT Flaherty, PA Ascierto, PD Nathan, P Rutkowski, O Leonov, C Dutriaux, M Mandalà, P Lorigan, PF Ferrucci, JJ Grob, N Meyer, H Gogas, D Stroyakovskiy, A Arance, JC Brase, S Green, T Haas, A Masood, E Gasal, A Ribas, D SchadendorfFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.